Reata Announces Enrollment of First Patient in Phase 2 Study of RTA 408 for the Treatment of Friedreich’s Ataxia
the powerhouse of the cell Irving, Texas based Reata Pharmaceuticals, whose mission is to translate innovative research into breakthrough medicines for difficult-to-treat diseases that have significant unmet needs, recently announced the enrollment of their first patient into MOXIe, their Phase 2 clinical study examining the safety, tolerability,…